Patients with end‐stage liver disease (ESLD) often have a high symptom burden. Historically,
palliative care (PC) services have been underused in this population. We investigated the …

Non-alcoholic fatty liver disease (NAFLD) affects 20–25% of the general population and is
associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD …

Tenofovir alafenamide fumarate (TAF) has high plasma stability resulting in fewer renal
adverse events compared to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB) …

Background No adjuvant treatment has been established for patients who remain at high
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …

Background Systemic therapies have improved the management of hepatocellular carcinoma,
but there is still a need to further enhance overall survival in first-line advanced stages. …

The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this
is rarely achieved with first-line treatment regimens because of an inability to disrupt …

Background and Aims Alcohol‐associated liver disease (ALD) is the leading cause of liver‐related
mortality in Latin America, yet the impact of public health policies (PHP) on liver …

Background & Aims The Glasgow-Blatchford score (GBS) and pre-endoscopy Rockall score
(pRS) are used in determining prognoses of patients with acute upper gastrointestinal …

BACKGROUND Cecal intubation is one of the goals of a quality colonoscopy; however,
many factors increasing the risk of incomplete colonoscopy have been implicated. The …

Background There is substantial variation in how histologic definitions and scoring systems
of non‐alcoholic fatty liver disease (NAFLD) are operationalised. Aim To develop a …